Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
venerdì, ottobre 30
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Acadia Pharmaceuticals Inc
ACAD
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$20.76
0.44
2.17%
Ult. Agg.: Oct 29, 4:42 PM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Utili:
I risultati di Q3 2026 tra 5 giorni da adesso in mer nov 4th, dopo la chiusura del mercato
Conference call:
Conference call programmata per tra 5 giorni alle 4:30 PM
Clicca per vedere il webcast
Acadia Pharmaceuticals Financials
Acadia Pharmaceuticals (ACAD) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
ACADIA Pharmaceuticals Raises FY2026 Sales Guidance from $1.220B-$1.280B to $1.240B-$1.300B vs $1.242B Est
ACADIA Pharmaceuticals (NASDAQ:ACAD) raises FY2026 sales outlook from $1.220 billion-$1.280 billion to $1.240 billion-$1.300 billion vs $1.242 billion estimate.
Benzinga Newsdesk
PRO
ACADIA Pharmaceuticals Q2 EPS $0.18 Beats $0.07 Estimate, Sales $307.959M Beat $295.857M Estimate
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.07 by 157.14 percent. This is a 12.5 percent increase over earnings of $0.16 per share
Benzinga Newsdesk
Earnings Scheduled For May 6, 2026
Benzinga Insights
PRO
ACADIA Pharmaceuticals Affirms FY2026 Sales Guidance of $1.220B-$1.280B vs $1.247B Est
ACADIA Pharmaceuticals (NASDAQ:ACAD) affirms FY2026 sales outlook from $1.220 billion-$1.280 billion to $1.220 billion-$1.280 billion vs $1.247 billion estimate.
Benzinga Newsdesk
PRO
ACADIA Pharmaceuticals Q1 EPS $0.02 Misses $0.05 Estimate, Sales $268.062M Miss $280.710M Estimate
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.05 by 60 percent. This is a 81.82 percent decrease over earnings of $0.11 per share
Benzinga Newsdesk
PRO
ACADIA Pharmaceuticals Sees FY2026 Sales $1.220B-$1.280B vs $1.203B Est
ACADIA Pharmaceuticals (NASDAQ:ACAD) sees FY2026 sales of $1.220 billion-$1.280 billion vs $1.203 billion analyst estimate.
Benzinga Newsdesk
